دورية
Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
| العنوان: | Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study |
|---|---|
| المؤلفون: | Wong, Sandy W., Bar, Noffar, Paris, Laura, Hofmeister, Craig C, Hansson, Markus, Santoro, Armando, Mateos, Maria-Victoria, Rodríguez-Otero, Paula, Lund, Johan, Encinas, Cristina, Yee, Andrew J., Oriol, Albert, Cerchione, Claudio, de la Rubia, Javier, Ferstl, Barbara, Carlson, Kristina, Ribas, Paz, Bermúdez, Arancha, Boss, Isaac W., Gaudy, Allison, Li, Shaoyi, Hsu, Kevin, Godwin, Colin D., Burgess, Michael R., San-Miguel, Jesús, Costa, Luciano J. |
| المصدر: | Blood; November 2022, Vol. 140 Issue: Supplement 1 p400-402, 3p |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood-2022-159009 |